JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million Successful disposition will facilitate continued strategic focus on high-value late-stage biopharma asset JAN101 for the treatment of peripheral artery disease (PAD) The transaction is expected to close on or before August 18, 2021 JanOne recently completed production of...
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX' Cash and cash equivalents of over $120 million as of merger close Registration trial for the treatment of relapsed/refractory...
ASLAN Pharmaceuticals Announces $18 Million Private Placement ASLAN today announced that it has entered into a securities purchase agreement to raise gross proceeds of approximately $18 million resulting from the sale of its ordinary shares through a private placement to new institutional investors, Vivo Capital and Surveyor Capital (a Citadel company). the...
NMTR had an incredible run over the past month. But it appears that it has been rejected at resistance, and will retrace fib levels back toward $1.00 before exiting this wedge. A defined risk strategy here is to buy the $1.00 puts, continue rolling them out, and then within the next month add the $1 calls to form a long straddle. Be careful as liquidity is low.
Under the radar biotech play. Confirmed Cup & Handle breakout. Bullish MACD cross is a technical buy signal. Technical price target .30+.
Potential reversal to the upside off of range lows Reward/Risk: 3.68/1 Entry: 81.94 or at a lower price Stop: 76.00 Target: 102.00 Options Play: April 16 85/90 Call Vertical
Oncolytics initiated with a Buy at H.C. Wainwright H.C. Wainwright analyst Patrick Trucchio initiated coverage of Oncolytics Biotech with a Buy rating and $15 price target. The company is "on the cusp of demonstrating potential to upend the treatment paradigms of several cancers," Trucchio tells investors in a research note. He believes Oncolytics is well...
Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Leading institutional investors committed a total of $105 million in private financings with Viracta Combined company expected to have...
Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Phase I/II Clinical Trial As announced in July 2020, the FDA had requested further manufacturing information, updated safety and efficacy data for all patients dosed, and provided direction on total viral load to be administered per patient. Based on the Company’s response to these requests, the...
$CLSN today announced that it has received Fast Track designation from the U.S. FDA for GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy currently in Phase II development for the treatment of advanced ovarian cancer. Fast Track designation is intended to facilitate the development and expedite the regulatory review of drugs to treat serious conditions...
The company’s lead drug candidate, linzagolix (branded as Yselty), is an orally administered GnRH receptor antagonist that has completed two Phase 3 studies, PRIMROSE 1 in the US and PRIMROSE 2 in both the US and Europe. The clinical trials enrolled 574 and 535 patients, respectively, and used doses of 100mg or 200mg to treat heavy menstrual bleeding associated...
AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case...
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform Partnerships will use Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery www.globenewswire.com
Why VistaGen Therapeutics Stock Soared yesterday The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy recommendation. Tsai also set a one-year price target of $6, nearly three times the price of VistaGen's shares at the market close on Wednesday. Why bullish? Tsai really likes the potential for VistaGen's lead ...
Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing finance.yahoo.com
Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference-February 16-18, 2021 finance.yahoo.com Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option. A total of 28,750,000 shares of its common stock were sold, including...
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule Currently, the Company is still not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of US$35 million; the Company has until June 8, 2021 to regain...
Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million, due to demand announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company at a price to the...